Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · Real-Time Price · USD
50.50
+3.50 (7.45%)
Nov 21, 2024, 1:16 PM EST - Market open

Company Description

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States.

Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain.

Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases.

Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Korro Bio, Inc.
Korro Bio logo
Country United States
Founded 2014
IPO Date Oct 3, 2019
Industry Biotechnology
Sector Healthcare
Employees 102
CEO Ram Aiyar

Contact Details

Address:
One Kendall Square, Building 600-700
Cambridge, Massachusetts 02139
United States
Phone 617 468 1999
Website korrobio.com

Stock Details

Ticker Symbol KRRO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $14.00
CIK Code 0001703647
CUSIP Number 500946108
ISIN Number US5009461089
Employer ID 47-2324450
SIC Code 2834

Key Executives

Name Position
Ram Aiyar MBA, Ph.D. Chief Executive Officer, President and Director
Nessan Bermingham Ph.D. Co-Founder and Independent Chairman of the Board
Dr. Jean-Francois Formela M.D., MBA Co-Founder and Independent Director
Vineet Agarwal M.B.A. Chief Financial Officer
Andrew Fraley Ph.D. Co-Founder and Advisor
Dr. Joshua Rosenthal Ph.D. Co-Founder and Advisor
Todd Chappell M.B.A. Chief Operating Officer
Jeffrey M. Cerio J.D., Pharm.D. Senior Vice President and General Counsel
Stephanie Engels Senior Vice President and Head of People and Culture
Marco A. Passini Ph.D. Vice President and Head of CNS biology

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 424B3 Prospectus
Nov 12, 2024 424B3 Prospectus
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 144 Filing